Alnylam Pharmaceuticals (ALNY) In-Depth Stock Report
The leading RNA interference company, priced on its transthyretin franchise, pipeline breadth, and path to sustained profitability.
Investment Summary
Every headline number this report produces, collected in one place before the analysis that derives them. All figures are computed live at page load, so this block reflects the market as of the moment you opened the page.
- Cardiomyopathy uptake exceeds expectations.
- Profitability expands quickly.
- Pipeline programs succeed.
- The platform yields additional approvals.
- Alnylam is the leading RNA interference company.
- Transthyretin disease drives growth.
- Competition and pipeline risk are the main risks.
- Product revenue and profitability are the key numbers.
- Alnylam pioneered RNA interference, a method that silences disease-causing genes, and has several approved medicines.
- Its largest opportunity is treating transthyretin amyloidosis, a disease affecting the heart and nerves.
- The company moved from long losses toward profitability as product revenue grew.
- A pipeline includes programs in cardiometabolic disease and neurological conditions.
- The equity debate is the pace of transthyretin cardiomyopathy uptake versus competition from other approaches.
Executive Summary
Alnylam has validated its platform with multiple approved products and licensing arrangements with major partners.
The transthyretin cardiomyopathy market is large, with newer treatment options expanding diagnosis and awareness.
RNAi drugs can be dosed infrequently, an attractive feature for chronic diseases, and the company uses a consistent delivery approach across programs.
Growth has driven rapid revenue expansion, and the company has been working toward sustained profit and cash generation.
The realistic thesis: a platform biotech with real commercial traction and high expectations, where sales growth in transthyretin disease and pipeline delivery determine outcomes.
Industry & Market Backdrop
The broader competitive and macro environment ALNY operates in — context a pure valuation table can't convey on its own.
Diagnosis of transthyretin cardiomyopathy is rising as awareness improves.
Competition includes stabilizers and other gene-silencing approaches.
Investors have favored biotechs with clear commercial traction and manageable cash burn.
Payer scrutiny of rare and specialty drug pricing continues.
Cardiometabolic RNAi programs could expand the market beyond rare disease.
Live Key Statistics
Pulled live from BriMindInvest's market-data pipeline at page load — the same feed that powers /analysis/ALNY. Fields the pipeline doesn't return this load are omitted rather than shown blank.
Business Overview
Marketed RNAi therapeutics for rare genetic and other diseases.
A transthyretin franchise targeting nerve and heart disease.
Partnered products and royalties.
A pipeline in cardiometabolic, neurologic, and other diseases.
Segment Deep Dive
A closer look at each reporting segment individually, rather than treating the business as a single undifferentiated revenue line.
This is the most important growth driver, with treatments for polyneuropathy and cardiomyopathy. Share gains depend on differentiation and physician education.
Approved drugs for other rare conditions provide steady revenue. They are smaller but demonstrate the platform's breadth.
Programs in hypertension and other conditions could widen the addressable population. Partnerships share development risk and provide royalties.
Capital Allocation & Balance Sheet Philosophy
How management has historically chosen to deploy cash — buybacks, dividends, R&D, and acquisitions — and what that reveals about capital discipline.
The company has funded itself through equity, partnerships, and royalty arrangements.
Profitability inflection reduces reliance on external capital.
R&D spending is significant and is directed toward platform expansion.
Convertible or structured financing has been used in the past.
Management & Governance
Leadership, incentive alignment, and governance structure — factors that shape execution risk independent of the underlying business model.
Scientific leadership and a long-term platform vision guide the company.
Management sets milestones for launches and profitability.
Governance is conventional for a biotech; review the proxy for details.
Execution on commercial scale-up is the main test.
See exactly how we get ALNY's fair-value range
| Method | Relevance | Implied Value |
|---|---|---|
| Our DCF Model | High | |
| Our P/E Based | Medium | |
| Our Book Value Based | Low | |
| Graham Number | Low | |
| ROIC Based | Low | |
| FCF Yield Based | High |
Forecast Revenue and Free Cash Flow
5-Year Monte Carlo Simulation
Included with a subscription or a one-time purchase of this Alnylam Pharmaceuticals report:
- Fair value from 7 methods, weighted by relevance to this business
- 5-year financial forecast and DCF/earnings sensitivity grids
- Decomposed AI Score, Monte Carlo simulation, and institutional/analyst data
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
Bull Case vs. Bear Case
- Cardiomyopathy uptake exceeds expectations.
- Profitability expands quickly.
- Pipeline programs succeed.
- The platform yields additional approvals.
- Partnerships provide royalty income.
- Competitors take share.
- Pricing or reimbursement is pressured.
- Pipeline setbacks occur.
- Launch execution disappoints.
- High valuation compresses on slower growth.
Related Reports
In-depth reports for other names in Alnylam Pharmaceuticals's comparable set.
4 catalysts and 4 risks we're tracking for ALNY
| Catalyst | Expected Impact | Timeframe |
|---|---|---|
Included with a subscription or a one-time purchase of this Alnylam Pharmaceuticals report:
- Catalyst list, each tagged with expected impact and timing
- Risk register scored by probability and severity
- 4 key metrics to watch before the next earnings report
$3.99 is less than one bad options trade — see the model before you commit real money. And it goes straight to the small team building this, not a hedge fund's marketing budget.
What Would Change Our Mind?
Specific, falsifiable triggers — not vague sentiment — that would move us toward or away from the bull case above.
- Cardiomyopathy uptake keeps accelerating
- Operating margins rise quickly
- Pipeline data broaden the market
- Competitors win a large share
- Growth slows abruptly
- Late-stage trials fail
Competitive Positioning
Alnylam's moat is RNAi intellectual property, delivery technology, and manufacturing know-how.
Ionis, Pfizer, BridgeBio, and others compete in transthyretin disease.
Physician familiarity and clinical outcomes drive prescribing.
The vulnerability is competition and reliance on a limited number of products.
Investor Decision Framework
A process for using this report, not a recommendation — how to weigh valuation, scenario spread, and your own risk tolerance.
- Own it if you want a platform biotech with commercial traction.
- Skip it if you cannot tolerate volatility or valuation risk.
- Track product revenue and patient uptake.
The BriMindInvest Edge
Why this report is different from asking a general-purpose AI chatbot about the stock.
- Every valuation number on this page is computed live from current market data through our own DCF, scoring, and Monte Carlo engines — not summarized or paraphrased from other analysts' reports the way a general chatbot would.
- The relevance-weighted fair value, reverse-DCF market-implied growth, fundamentals-based Monte Carlo, and scenario tables above are proprietary calculations you cannot get by asking a general-purpose AI for "ALNY fair value" — those answers come from web summaries of other people's price targets, not a live, disclosed-assumption model.
- Our 1-year price-target model has a real, published backtest (see Model Track Record above where covered) — we show our work and our error rate rather than asserting accuracy.
- Numbers here are refreshed every time you load the page, not cached from a training cutoff months or years in the past.
Data Sources & Methodology
Valuation, price, and financial-statistics data in this report are fetched live from our production market-data pipeline (Yahoo Finance and Finnhub) at the time you loaded this page. The AI Score is a percentile ranking against our full covered stock universe, recomputed nightly. The fundamentals-based Monte Carlo and Bull/Base/Bear scenarios randomize growth rate, discount rate, and terminal growth around the same disclosed DCF assumptions used in the valuation table — they are not derived from resampled historical stock returns. The secondary historical-volatility simulation (2,000 bootstrap paths, seeded for reproducibility) uses the stock's own historical monthly returns and is shown separately because it measures a different thing (volatility) than the fundamentals-based model (intrinsic value).
This report is for informational and educational purposes only and does not constitute financial, investment, or tax advice, or a recommendation to buy or sell any security. All valuation models, price targets, and simulations are estimates based on historical and current data; actual results will differ, potentially substantially. Investing involves risk, including loss of principal. See our full Methodology and Disclaimer.
Free vs. Premium: What You're Getting
- Narrative overview and general bull/bear framing
- Headline price and basic company facts
- No live valuation model, AI Score, or forecast table
- Relevance-weighted fair value range and reverse-DCF market-implied growth
- 5-year financial forecast, DCF sensitivity grid, and Bull/Base/Bear scenario table
- Fundamentals-based Monte Carlo and decomposed AI Score with sub-factor components
- Real, published backtested accuracy where ALNY is in our coverage set
Glossary of Key Terms
Plain-English definitions for the terms used throughout this report, for readers newer to equity valuation.
Frequently Asked Questions
Unlock Full AI-Powered Analysis
Get AI prediction signals, unlimited stock comparisons, portfolio analytics, and personalized watchlists — free for 14 days, no credit card required.
14-day free trial · No credit card required · Cancel anytime
Not ready to sign up? Get one free email a week instead.